New injection HRS9531 tested in teens with obesity
NCT ID NCT07559136
First seen May 01, 2026 · Last updated May 24, 2026 · Updated 3 times
Summary
This early-stage trial studies an injectable drug called HRS9531 in Chinese adolescents aged 12 to 17 who have obesity. The main goal is to see if the drug is safe and how it moves through the body. Participants will receive either the drug or a placebo, and researchers will track side effects, weight changes, and other health measures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact
Conditions
Explore the condition pages connected to this study.